Vaccination Against RhoC in Prostate Cancer Patients Induces Potent and Long-Lasting CD4⁺ T Cell Responses with Cytolytic Potential in the Absence of Clinical Efficacy: A Randomized Phase II Trial

<b>Background</b>: A previous phase I/II study demonstrated potent and long-term immune responses in men with prostate cancer following vaccination with a 20mer synthetic peptide (RV001) derived from the Ras homolog gene family member C protein (RhoC). Moreover, a fraction of patients experienced pr...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Sara Fresnillo Saló, Juliane Schuhmacher, Anne Rahbech, Sara Ram Pedersen, Tina Seremet, Valero Andreu Matillas, Anna Schöllhorn, Andreas Røder, Steffen Wad Jørgensen, Klaus Brasso, Cécile Gouttefangeas, Per thor Straten, on behalf of the RhoVac-002 Study Group
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2025-04-01
Edice:	Vaccines
Témata:	cancer vaccine RhoC CD4<sup>+</sup> T cells
On-line přístup:	https://www.mdpi.com/2076-393X/13/4/390
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!